- Practice your dividend trading strategies and win cash in our stock game.
Cramer's outlook on drug stocks.
Despite a Phase 3 stumble, BMY stock is holding up.
Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.
Late stage trials failed to show significant statistical efficacy.